Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2
-
Published:2020-04
Issue:2
Volume:20
Page:e173-e180
-
ISSN:1526-8209
-
Container-title:Clinical Breast Cancer
-
language:en
-
Short-container-title:Clinical Breast Cancer
Author:
Rugo Hope S.,
Finn Richard S.,
Gelmon Karen,
Joy Anil A.,
Harbeck Nadia,
Castrellon Aurelio,
Mukai Hirofumi,
Walshe Janice M.,
Mori Ave,
Gauthier Eric,
Lu Dongrui RayORCID,
Bananis Eustratios,
Martin Miguel,
Diéras Véronique
Funder
Plexxikon
MacroGenics
OBI Pharma
Eisai
Pfizer
Novartis
Eli Lilly
Roche, and Merck
Roche and Novartis
Daiichi Sankyo
Nippon Kayaku
Pfizer Inc.
Pfizer Inc
Subject
Cancer Research,Oncology
Reference11 articles.
1. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3);Cardoso;Ann Oncol,2017
2. Ibrance® (palbociclib). Full Prescribing Information,2018
3. Ibrance Product Monograph. Kirkland, Quebec: Pfizer Canada Inc,2018
4. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro;Finn;Breast Cancer Res,2009
5. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study;Finn;Lancet Oncol,2015
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献